Structural characterization and anticancer activity on osteosarcoma of Zn(II) coordination polymer

Synthesis, Crystal Structure, Hirschfeld Surface Analysis and Catalytic Activity of a New Binuclear Zn(II) Complex Based on Homophthalic Acid and 2,2'-Bipyridine Ligands

A new binuclear Zn(II) complex, [Zn2L2(BIPY)2(H2O)2](1) (H2L = homophthalic acid, BIPY = 2,2'-bipyridine) has been synthesized by one-pot method of homophthalic acid, 2,2'-bipyridine, zinc acetate dihydrate, and NaOH in water/ethanol (v:v = 1:1) solution. The structure of complex (1) was characterized by IR and X-ray single-crystal diffraction analysis. The results show that each Zn(II) ion is five-coordinated with two carboxylic O atoms from two homophthalate ligands (O2, O3 or O2a, O3a), two N atoms from two 2,2'-bipyridine ligands (N1, N2 or N1a, N2a) and one O atom from coordinated water molecule (O5 or O5a), and forms a distorted trigonal bipyramid coordination geometry. Complex (1) forms 1D chained structure and 3D network structure by the p-p interaction of 2,2'-bipyridine ligands. The Hirschfeld surface analysis of complex (1) was calculated. The catalytic performance of complex (1) has also been investigated for the oxidation of benzyl alcohol under O2 atmosphere. The optimal reaction temperature and pressure were 100 °C and 0.3 MPa for complex (1). Copyright © 2022 by Authors, Published by BCREC Group. This is an open access article under the CC BY-SA License (https://creativecommons.org/licenses/by-sa/4.0). 

Synthesis, Crystal Structure and Catalytic Activity of Tri-Nuclear Zn(II) Complex Based on 6-Phenylpyridine-2-carboxylic Acid and Bis(4-pyridyl)amine Ligands

A new trinuclear Zn (II) complex, [Zn3(L1)4(L2)2(CH3COO)2] (1) (HL1 = 6-phenylpyridine-2-carboxylic acid, L2 = bis(4-pyridyl)amine) has been synthesized by 6-phenylpyridine-2-carboxylic acid, NaOH, bis(4-pyridyl)amine and Zn(CH3COO)2•2H2O. The complex 1 has also been structural characterized by elemental analysis and single crystal X-ray diffraction. The results reveals that complex 1 is made up of three Zn(II) ions, four L1 ligands, two L2 ligands and two CH3COO- anions. In 1, both Zn1 ion and Zn1a ion are five-coordinated with two O atoms from two different L1 ligands, two N atoms from two different L1 ligands, and one N atoms from bis(4-pyridyl)amine ligand, respectively, and forms a distorted trigonal biyramid geometry. And Zn2 ion is four-coordinated with two O atoms from two different CH3COO− anions and two N atoms from two different L2 ligands, forming a distorted tetrahedral geometry. Complex 1 displays a 3D network structure by the intermolecular N−H···O hydrogen bonds. The catalytic performance for oxidation of benzyl alcohol with O2 was studied under mild reaction conditions using complex 1 as catalyst. The results demonstrated that the catalysts were very active, and the yield of benzaldehyde was 50.8% at 90 °C with THF as solvent under 0.5 MPa O2 within 3 h. Copyright © 2022 by Authors, Published by BCREC Group. This is an open access article under the CC BY-SA License (https://creativecommons.org/licenses/by-sa/4.0). 

Two Zn(II) coordination polymers with anticancer drug norcantharidin as ligands for cancer chemotherapy

Here two Zn(II) coordination polymers [Zn₂₀(DMCA)₁₂]O₁₂ (DMCA = demethylcantharic acid, DMCA-Zn1) and [Zn(DMCA)](H₂O)₂ (DMCA-Zn2) are synthesized from a broad-spectrum anticancer drug norcantharidin (NCTD) and Zn(NO₃)₂·6H₂O under solvothermal conditions. By mechanical grinding with a biocompatible polymeric surfactant F127, ultrasonic treatment and filtration, DMCA-Zn1 and DMCA-Zn2 can be transformed into stable nanoparticles (DMCA-Zn1 NPs and DMCA-Zn2 NPs) suspended in water with average diameters of around 190 nm and 162 nm for drug delivery. The in vitro evaluation indicates that DMCA-Zn1 NPs and DMCA-Zn2 NPs can enter into HepG2 and Hep3B cancer cells via endocytosis and inhibit their proliferation. Meanwhile they exhibit relatively low toxicity to L927 normal cells. The in vivo evaluation confirms that DMCA-Zn1 NPs and DMCA-Zn2 NPs can more effectively inhibit the growth of Hep3B tumors with relatively few side effects compared with free NCTD. This approach can be extended to other anticancer drugs to construct nanodrug delivery systems for cancer treatment.

The crystal structure of catena-poly[(m2-4,4′-bipyridine-κ2 N:N)-bis(6-phenylpyridine-2-carboxylato-κ2 N,O) zinc(II)], C34H24N4O4Zn

C34H24N4O4Zn, monoclinic, I2/a (no. 15), a = 18.2546(14) Å, b = 11.0510(7) Å, c = 16.1874(15) Å, β = 119.605(11)°, V = 2839.2(5) Å3, Z = 4, R gt (F) = 0.0302, wR ref (F 2) = 0.0694, T = 200 K.